Table 1: Baseline characteristics
	London (N=30)	NINDS treated (p-value) (N=168)	NINDS placebo (p-value) (N=165)
Mean age, (y+/-SD)	70+/-10	69+/-12	66+/-13 (<0.1)
Female (%)	63	43	42
White (%)	100	69	66
Baseline NIHSS (median)	14	14	15
Treated at 0-90 minutes (%)	3	51 (0.000001)	47 (0.000007)
Treated at 91-180 minutes (%)	90	49	53
Treated at 181-195 minutes	7	0	0
Hypertension (%)	60	67	67
Smoking (%)	27	27	35
Prior stroke (%)	30	12	9
Diabetes (%)	20	20	20
Coronary disease (%)	30	22	20
Atrial fibrillation (%)	17	20	16
Anti-platelet use (%)	37	40	26
Suspected lacunar syndrome (%)	17	14	9

Table 2: Outcomes
	London % (N=30)	NINDS treated % (p-value)* (N=168)	NINDS placebo % (p-value)* (N=165)
24 hours
þ4 point improvement or normal	63	48 (0.11)	39 (0.02)
Three months
NIHSSS
0-1	37	31 (0.46)	20 (0.03)
2-8	43	30	32
>8	7	22	27
Death	13	17	21
death or severe disability	20	39 (0.04)	48 (0.004)
modified Rankin
0-1	37	39 (0.79)	26 (0.23)
2-3	37	21	25
4-5	13	23	27
Death	13	17	21
death or severe disability	27	40 (0.15)	48 (0.03)
NIHSSS= National Institute of Health Stroke Scale score. Severe disability is defined as an NIHSSS > 8 or modified Rankin score equal to 4 or 5. *All statistical comparisons are made in reference to the London group.

Table 3: Complication rates
	London % (N=30)	NINDS treated % (N=312)	NINDS placebo % (N=312)
Symptomatic ICH	0	6.4	0.6
Fatal ICH	0	2.9	0.3
Asymptomatic ICH	3.3	4.5	2.9
Petechial hemorrhage	23.3	NA	NA
Major systemic hemorrhage	3.3	1.6	0
ICH = intracranial hemorrhage: NA = not available: p>0.05 for all comparisons to London group